Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders

Andrea CALCAGNO; Ivano Dal Conte; Dario Cattaneo; Roberto Testi; Massimiliano Mistrangelo; Cristina Gervasoni; Amedeo de Nicolò; Stefano Bonora; Antonio D'Avolio; Giovanni Di Perri

doi:10.1128/AAC.01902-20

Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders

Andrea CALCAGNO
, Ivano Dal Conte
, Dario Cattaneo
, Roberto Testi
, Massimiliano Mistrangelo
, Cristina Gervasoni
, Amedeo de Nicolò
, Stefano Bonora
, Antonio D'Avolio
, Giovanni Di Perri

Department of Translational Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Four pre-exposure prophylaxis (PrEP) users with gastro-intestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite a self-reported high adherence, trough plasma tenofovir concentrations (after a supervised intake) were significantly lower than those observed in PrEP recipients without gastrointestinal disorders [21 (±9.1) vs. 138 (±85) ng/mL]. PrEP users with gastrointestinal disorders may need increased TDF doses or alternative prophylactic measures.

Original language	English
Pages (from-to)	e01902-20-e01902-20
Number of pages	5
Journal	Antimicrobial Agents and Chemotherapy
Volume	65
Issue number	1
DOIs	https://doi.org/10.1128/AAC.01902-20
Publication status	Published - 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1128/AAC.01902-20

https://hdl.handle.net/11579/216866

Cite this

@article{5070f74862ce4be580274e3697d913ce,

title = "Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders",

abstract = "Four pre-exposure prophylaxis (PrEP) users with gastro-intestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite a self-reported high adherence, trough plasma tenofovir concentrations (after a supervised intake) were significantly lower than those observed in PrEP recipients without gastrointestinal disorders [21 (±9.1) vs. 138 (±85) ng/mL]. PrEP users with gastrointestinal disorders may need increased TDF doses or alternative prophylactic measures.",

author = "Andrea CALCAGNO and \{Dal Conte\}, Ivano and Dario Cattaneo and Roberto Testi and Massimiliano Mistrangelo and Cristina Gervasoni and \{de Nicol{\`o}\}, Amedeo and Stefano Bonora and Antonio D'Avolio and \{Di Perri\}, Giovanni",

year = "2021",

doi = "10.1128/AAC.01902-20",

language = "English",

volume = "65",

pages = "e01902--20--e01902--20",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "1",

}

TY - JOUR

T1 - Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders

AU - CALCAGNO, Andrea

AU - Dal Conte, Ivano

AU - Cattaneo, Dario

AU - Testi, Roberto

AU - Mistrangelo, Massimiliano

AU - Gervasoni, Cristina

AU - de Nicolò, Amedeo

AU - Bonora, Stefano

AU - D'Avolio, Antonio

AU - Di Perri, Giovanni

PY - 2021

Y1 - 2021

N2 - Four pre-exposure prophylaxis (PrEP) users with gastro-intestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite a self-reported high adherence, trough plasma tenofovir concentrations (after a supervised intake) were significantly lower than those observed in PrEP recipients without gastrointestinal disorders [21 (±9.1) vs. 138 (±85) ng/mL]. PrEP users with gastrointestinal disorders may need increased TDF doses or alternative prophylactic measures.

AB - Four pre-exposure prophylaxis (PrEP) users with gastro-intestinal disorders (sleeve gastrectomy, terminal ileitis, celiac disease or chronic diarrhea) and receiving oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) were included. Despite a self-reported high adherence, trough plasma tenofovir concentrations (after a supervised intake) were significantly lower than those observed in PrEP recipients without gastrointestinal disorders [21 (±9.1) vs. 138 (±85) ng/mL]. PrEP users with gastrointestinal disorders may need increased TDF doses or alternative prophylactic measures.

UR - https://iris.uniupo.it/handle/11579/216866

U2 - 10.1128/AAC.01902-20

DO - 10.1128/AAC.01902-20

M3 - Article

SN - 0066-4804

VL - 65

SP - e01902-20-e01902-20

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 1

ER -

Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this